“$150B Buyback! $NVDA Climbs as Futures Slip | PreMarket Playbook + T3 Live | September 29, 2026”
IOVA shows strong technical momentum and fundamental catalysts from raised guidance, but presents execution challenges due to prior gains and low options liquidity.
The first one that I have is IOVA on earnings. Now, this stock is definitely one to keep an eye on right now. Uh it's a biotech stock. I've been trading it um actually up eight to 10 and then you ever have a stock that gets away from you where you're trading it and all of a sudden you stop for a couple days and it's higher and you're like oh I got to watch it again and then it's higher and you feel like how do I get back in?
IOVA is that kind of stock and here it goes again. Um up uh today it's up on uh fully year revenue guidance attributed to sustained demand for the drug.